Thyroid hormone autoantibodies: are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments?

P. Mondello, M. Mian, V. Pitini, S. Cuzzocrea, A. Sindoni, M. Galletti, M. Mandolfino, D. Santoro, S. Mondello, C. Aloisi, G. Altavilla, S. Benvenga



Unlike cytotoxic agents, novel antineoplastic drugs can variably affect thyroid function and so impair patient outcomes. However, the widely used standard thyroid tests have demonstrated low sensitivity for detecting early thyroid damage that leads to dysfunction of the gland. To find a more reliable thyroid marker, we assessed the presence of antibodies binding thyroid hormones (THAbs) in a cancer population undergoing potentially thyrotoxic treatment.


From April 2010 to September 2013, 82 patients with hematologic malignancies treated with tyrosine kinase inhibitors or immunoregulatory drugs were recruited. Healthy volunteers (n = 104) served as control subjects. Thyroid function, autoimmunity tests, THAbs, and thyroid sonography were assessed once during treatment.


Overall, THAb positivity was recorded in 13% of the entire cohort. In most cases, the THAbs were of a single type, with a predominance of T3 immunoglobulin G. More specifically, THAbs were detected in 11 cancer patients; and abnormal levels of thyroid-stimulating hormone, thyroglobulin antibody, and thyroperoxidase antibody were detected in 6 (p = 0.05), 0 (p = 0.0006), and 2 cancer patients (p = 0.001) respectively. Ultrasonographic alterations of the thyroid were observed in 12 cancer patients. In contrast, of the 104 healthy control subjects, only 1 was positive for THAbs (1%).


We have demonstrated for the first time that THAbs are a reliable marker of early thyroid dysfunction when compared with the widely used standard thyroid tests. A confirmatory prospective trial aiming at evaluating THAbs at various time points during treatment could clarify the incidence and timing of antibody appearance.


THAb; tyrosine kinase inhibitors; immunoregulatory drugs; hematologic malignancies

Full Text:



Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)